OCP 8101
Alternative Names: OCP-8101Latest Information Update: 20 Oct 2021
At a glance
- Originator Oncocross; Unknown
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 07 Oct 2021 Early research in Unspecified in South Korea (unspecified route) before October 2021 (Oncocross' pipeline, October 2021)